Scholarlink

Objectives <p>To determine the prevalence and persistence of islet autoantibodies and explore their HLA associations among patients with type 1 diabetes (T1DM).</p> Methods <p>Islet autoantibodies (GAD-65A, IA-2A, and ZnT8A) and fasting C-peptide (FCP) levels were assessed at baseline (prevalence) and 2–5 y, 5–10 y, and &gt; 10 y from the baseline (persistence). HLA associations were evaluated for individual islet autoantibodies and their persistence.</p> Results <p>The authors evaluated 366 participants with a median diabetes duration of 6 y at baseline. The overall positivity for any of the three autoantibodies was 67.5%, which increased to 76% in a subset of patients (<i>n</i> = 125) with diabetes duration ≤ 2 y. In the persistence analysis, positivity for IA-2A and ZnT8A declined earlier compared to GAD-65A (median survival times of 11, 12, and 31 y). The median survival time for FCP (time to undetectable levels) was 5 y, with significantly shorter survival in individuals with younger (&lt; 10 y) age at diagnosis and in the autoantibody-positive group. The HLA-DRB1*03 allele was significantly associated with the GAD-65A, and the HLA-DRB1*04 allele with the ZnT8A. There was no association of HLA-DRB1 status with islet autoantibody persistence.</p> Conclusions <p>Nearly two in every three patients evaluated at a median disease duration of 6 y tested positive for one or more islet autoantibodies. GAD-65A was more prevalent and relatively stable over time, serving as a robust diagnostic marker for T1DM. A more rapid decline in beta cell reserve was noted in individuals with younger age at diagnosis and islet autoantibody positivity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pattern and Persistence of Islet Autoantibodies and their Immunogenetic Association among Type 1 Diabetes Patients from North India

  • 期刊论文

  • 发表日期：

    2025年12月12日

查看全文
  • Shreya Sharma,
  • Alpesh Goyal,
  • Uma Kanga,
  • Neeraj Kumar,
  • Dona Maria Philips,
  • Pradeep A. Praveen,
  • Ravinder Goswami,
  • Nikhil Tandon

摘要

Objectives

To determine the prevalence and persistence of islet autoantibodies and explore their HLA associations among patients with type 1 diabetes (T1DM).

Methods

Islet autoantibodies (GAD-65A, IA-2A, and ZnT8A) and fasting C-peptide (FCP) levels were assessed at baseline (prevalence) and 2–5 y, 5–10 y, and > 10 y from the baseline (persistence). HLA associations were evaluated for individual islet autoantibodies and their persistence.

Results

The authors evaluated 366 participants with a median diabetes duration of 6 y at baseline. The overall positivity for any of the three autoantibodies was 67.5%, which increased to 76% in a subset of patients (n = 125) with diabetes duration ≤ 2 y. In the persistence analysis, positivity for IA-2A and ZnT8A declined earlier compared to GAD-65A (median survival times of 11, 12, and 31 y). The median survival time for FCP (time to undetectable levels) was 5 y, with significantly shorter survival in individuals with younger (< 10 y) age at diagnosis and in the autoantibody-positive group. The HLA-DRB1*03 allele was significantly associated with the GAD-65A, and the HLA-DRB1*04 allele with the ZnT8A. There was no association of HLA-DRB1 status with islet autoantibody persistence.

Conclusions

Nearly two in every three patients evaluated at a median disease duration of 6 y tested positive for one or more islet autoantibodies. GAD-65A was more prevalent and relatively stable over time, serving as a robust diagnostic marker for T1DM. A more rapid decline in beta cell reserve was noted in individuals with younger age at diagnosis and islet autoantibody positivity.